AZN•benzinga•
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
Summary
BridgeBio's acoramidis wins Japan's approval for ATTR-CM. Phase 3 data show a 42% reduction in key heart-related events. AstraZeneca's Alexion to market it.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 27, 2025 by benzinga